Abstract:Purpose: Serine metabolism is frequently dysregulated in many types of cancers and the tumor suppressor p53 is recently emerging as a key regulator of serine metabolism. However, the detailed mechanism remains unknown. Here, we investigate the role and underlying mechanisms of how p53 regulates the serine synthesis pathway (SSP) in bladder cancer (BLCA). Methods: Two BLCA cell lines RT-4 (WT p53) and RT-112 (p53 R248Q) were manipulated by applying CRISPR/Cas9 to examine metabolic differences under WT and mutant p53 status. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and non-targeted metabolomics analysis were adopted to identify metabolomes changes between WT and p53 mutant BLCA cells. Bioinformatics analysis using the cancer genome atlas and Gene Expression Omnibus datasets and immunohistochemistry (IHC) staining was used to investigate PHGDH expression. Loss-of-function of PHGDH and subcutaneous xenograft model was adopted to investigate the function of PHGDH in mice BLCA. Chromatin immunoprecipitation (Ch-IP) assay was performed to analyze the relationships between YY1, p53, SIRT1 and PHGDH expression. Results: SSP is one of the most prominent dysregulated metabolic pathways by comparing the metabolomes changes between wild-type (WT) p53 and mutant p53 of BLCA cells. TP53 gene mutation shows a positive correlation with PHGDH expression in TCGA-BLCA database. PHGDH depletion disturbs the reactive oxygen species homeostasis and attenuates the xenograft growth in the mouse model. Further, we demonstrate WT p53 inhibits PHGDH expression by recruiting SIRT1 to the PHGDH promoter. Interestingly, the DNA binding motifs of YY1 and p53 in the PHGDH promoter are partially overlapped which causes competition between the two transcription factors. This competitive regulation of PHGDH is functionally linked to the xenograft growth in mice. Conclusion: YY1 drives PHGDH expression in the context of mutant p53 and promotes bladder tumorigenesis, which preliminarily explains the relationship between high-frequency mutations of p53 and dysfunctional serine metabolism in bladder cancer.

YY2/PHGDH axis suppresses tumorigenesis by inhibiting tumor cell de novo serine biosynthesis

Yin and Yang of YY1 regulation on tumor metabolic reprogramming

Transcription factor YY1 promotes cell proliferation by directly activating the pentose phosphate pathway.

Yin Yang 1 promotes the Warburg effect and tumorigenesis via glucose transporter GLUT3

Serine Metabolic Reprogramming in Tumorigenesis, Tumor Immunity, and Clinical Treatment.

Yin Yang 1 Facilitates Hepatocellular Carcinoma Cell Lipid Metabolism And Tumor Progression By Inhibiting Pgc-1 Beta-Induced Fatty Acid Oxidation

YY2‐DRP1 Axis Regulates Mitochondrial Fission and Determines Cancer Stem Cell Asymmetric Division

YY1-MIR372-SQSTM1 Regulatory Axis in Autophagy

Methylation of transcription factor YY2 regulates its transcriptional activity and cell proliferation

Transcription factor Yin Yang 2 is a novel regulator of the p53/p21 axis.

Suppression of nuclear GSK3 signaling promotes serine/one-carbon metabolism and confers metabolic vulnerability in lung cancer cells

YY1 Targets Tubulin Polymerisation-Promoting Protein to Inhibit Migration, Invasion and Angiogenesis in Pancreatic Cancer Via P38/mapk and PI3K/AKT Pathways

YTHDF2 exerts tumor-suppressor roles in gastric cancer via up-regulating PPP2CA independently of m 6 A modification

Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer

A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related hepatocellular carcinoma.

Yin Yang 1 Promotes Mtorc2-Mediated AKT Phosphorylation.

SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer

Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer

The role of YY1 in oncogenesis and its potential as a drug target in cancer therapies.

YY1 promotes pancreatic cancer cell proliferation by enhancing mitochondrial respiration

YTHDF1 in Tumor Cell Metabolism: An Updated Review